drugset / Trial / NCT03298464

Study of NGM313 in Obese Participants

NCT03298464

Phase 1 Completed 25 enrolled NGM Biopharmaceuticals, Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants

Timeline

Start
2017-09-11
Primary completion
2018-06-19
Completion
2018-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject NGM313 Unknown Subcutaneous
Comparator Pioglitazone Small molecule Oral

Indications